Squarepoint Ops LLC Has $106,000 Stock Holdings in Altimmune, Inc. (NASDAQ:ALT)

Squarepoint Ops LLC decreased its position in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 76.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,706 shares of the company's stock after selling 46,982 shares during the period. Squarepoint Ops LLC's holdings in Altimmune were worth $106,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of ALT. SBI Securities Co. Ltd. bought a new position in shares of Altimmune during the 4th quarter valued at approximately $45,000. Virtus ETF Advisers LLC purchased a new position in shares of Altimmune during the fourth quarter valued at $60,000. Cullen Frost Bankers Inc. purchased a new position in shares of Altimmune during the fourth quarter valued at $72,000. KLP Kapitalforvaltning AS purchased a new position in Altimmune in the fourth quarter valued at about $81,000. Finally, Raymond James Financial Inc. purchased a new position in Altimmune in the fourth quarter valued at about $88,000. Institutional investors own 78.05% of the company's stock.

Altimmune Trading Down 3.2%

Shares of NASDAQ:ALT traded down $0.23 on Friday, hitting $6.92. The company had a trading volume of 4,326,088 shares, compared to its average volume of 2,885,369. Altimmune, Inc. has a 52-week low of $3.55 and a 52-week high of $11.16. The business has a 50 day moving average of $5.28 and a 200 day moving average of $6.31. The company has a market cap of $561.26 million, a PE ratio of -4.46 and a beta of 0.58.

Altimmune (NASDAQ:ALT - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.09. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same period in the prior year, the firm posted ($0.34) earnings per share. As a group, equities analysts predict that Altimmune, Inc. will post -1.35 EPS for the current year.

Analyst Ratings Changes

ALT has been the subject of a number of research reports. Wall Street Zen raised Altimmune from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. HC Wainwright reiterated a "buy" rating and set a $12.00 price objective on shares of Altimmune in a research note on Thursday, April 3rd. Finally, William Blair reissued a "market perform" rating on shares of Altimmune in a research note on Friday, March 14th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $20.20.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.